- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03114852
Familiar Renal Disease, Epidemiology and Genetics in Niteroi/Rio de Janeiro (REGENT)
September 19, 2020 updated by: Jorge R Almeida, MD, Universidade Federal Fluminense
The REGENT Study: Familiar Renal Disease, Epidemiology and Genetics in Niteroi/Rio de Janeiro
The REGENT study (Familiar Renal Disease, Epidemiology and Genetics in Niteroi/Rio de Janeiro) is a epidemiological study that try to identify and clinically describe questions about genetic renal diseases in a southeast Brazilian population undergoing renal replacement therapy.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
In Brazil, several kidney diseases have unknown etiological diagnosis, among them, hereditary renal diseases.
The lack of technical-scientific knowledge and patients' access to the health service hinder the correct diagnosis, so that hundreds of patients with chronic kidney disease (CKD) are unaware of the origin of their kidney problems.
The objective of this REGENT study (Renal epidemiology and genetics in Niteroi) is to identify and characterize the cases of possible inheritance of CKD in patients undergoing dialysis or kidney transplant treatment in the metropolitan region II of the state of Rio de Janeiro.
In this metropolitan region, based in the city of Niteroi, there are 10 hemodialysis clinics accounting for approximately 1500 - 1800 patients.
There is a central Hospital that works as an official reference center for all those CKD patients (Hospital Universitario Antonio Pedro).
This hospital belongs to the Universidade Federal Fluminense, an academic research institution, where this project will be executed.
There is also a kidney transplant unit working at the Hospital Universitario Antonio Pedro.
Interviews, sociodemographic and clinical data collection will be performed in patients with CKD from these centers.
The interview contains questions about family CKD: Does any family member undergo hemodialysis or peritoneal dialysis?
Does any family member do/did conservative treatment for CKD? Has any family member had a kidney transplant?
Has any family member died due to chronic kidney disease?
In cases of any affirmative answer to one of the above questions, patients will be classified as a "family index case".
The cases of familial kidney disease caused by diabetes, and polycystic kidney disease will be excluded.
So, the remaining cases will be considered as "index cases" to be more described and characterized.
In this way, an affirmative response to the survey will create a group of familial CKD, and it will allow us to identify them as a suspected genetic kidney disease.
These patients will be analyzed as a group, and clinical histories and blood tests to genetic renal diseases will also be performed, when possible, depending on the availability.
From these identified index cases, we will try to create familiar clinical description of each individual in every family.
A new outpatient section is being created at the Hospital Universitario Antonio Pedro to take multidisciplinary care of the relatives and entire families in a special type of family primary care.
Study Type
Observational
Enrollment (Actual)
1308
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
RIO DE Janeiro
-
Niteroi, RIO DE Janeiro, Brazil, 24033900
- Universidade Federal Fluminense
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 80 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
The population to be studied will be formed by southeast Brazilians that are on renal replacement therapy as dialysis or kidney transplantation.
Such patients with renal diseases will answer a questionnaire about familial involvement.
Some of them will be characterized as a familial index case of not yet determined genetic kidney disease.
Description
Inclusion Criteria:
- Brazilian patients underwent any type of renal replacement therapy, dialysis or kidney transplantation living in the area of Niteroi/Rio de Janeiro.
- Relatives among the familial people of the index cases.
Exclusion Criteria:
- Diabetic Nephropathy
- Non-familial cases of known Glomerulonephritis
- Refuse in participating of interview and blood collection to genetic tests
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Family-Based
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
CKD patients
'blood collection' Patients with chronic kidney disease in renal replacement therapy living in the sanitary administrative region of Niteroi/Rio de Janeiro. They will be interviewed about past history of familiar renal disease. They will have blood functional renal biochemistry analysed. |
They will have blood tested to renal genetic diseases
|
|
Renal Familiar Disease
'blood collection' They will have blood tested to renal genetic diseases
|
They will have blood tested to renal genetic diseases
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Frequency and numbers of patients with renal familial diseases that are on renal replacement therapy in southeast Brazil.
Time Frame: The familial epidemiological results will be ready up to 24 months form the start of the study.
|
We will proceed a clinical interview using a questionnaire focused on the family history, among each Brazilian patients from dialysis or transplant center from the region of Niteroi/Rio de Janeiro.
Patients with a positive history of familial disease will be included as a "case of familial renal disease".
The results of the interviews will be analysed to create a report about incidence and prevalence of genetic renal disease among the southeast Brazilian people.
At the same time we are creating a genetic reservoir to characterization of renal diseases in southeast of Brazil and we are also creating the basis to a cohort study based these families, through a new recently created outpatient unit to take care of familial renal diseases to follow all these involved renal families.
|
The familial epidemiological results will be ready up to 24 months form the start of the study.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Frequency of uromodulin and APOL-1 mutation in southeast Brazilian patients underwent renal replacement therapy
Time Frame: From the time to DNA extraction, by using molecular studies, the DNA samples of each index cases will be analyised to uromodulin and APOL1, up to 48 months.
|
A complete mutation analysis, with identification of polimorphism SNPs to uromodulin and APOL-1 will be place as an initial specific protocol by using extracted DNA from the familial index cases.
|
From the time to DNA extraction, by using molecular studies, the DNA samples of each index cases will be analyised to uromodulin and APOL1, up to 48 months.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jorge R Almeida, MD, PhD, Universidade Federal Fluminense
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 20, 2017
Primary Completion (Actual)
December 20, 2019
Study Completion (Actual)
September 19, 2020
Study Registration Dates
First Submitted
March 20, 2017
First Submitted That Met QC Criteria
April 10, 2017
First Posted (Actual)
April 14, 2017
Study Record Updates
Last Update Posted (Actual)
September 22, 2020
Last Update Submitted That Met QC Criteria
September 19, 2020
Last Verified
August 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- REGENT study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Diseases
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
University of North Carolina, Chapel HillLantheus Medical ImagingCompletedChronic Kidney Diseases | Cystic Kidney DiseaseUnited States
-
Pang PengGuangdong Provincial Hospital of Traditional Chinese MedicineUnknownEnd-Stage Kidney Disease | Chronic Kidney FailureChina
-
Universiti Putra MalaysiaRecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic DialysisMalaysia
-
George Washington UniversityCareDx; VirginiaBio Analytics, LLCTerminatedKidney Diseases | Kidney Failure, Chronic | Kidney Transplant Infection | Kidney Transplant Rejection | Kidney Injury | Kidney Disease, Chronic | Kidney Failure | Kidney Failure, Acute | Kidney Transplant; Complications | Kidney IschemiaUnited States
-
Emory UniversityNorthwestern University; Columbia University; Satellite Healthcare; Norman S. Coplon...CompletedKidney Failure, Chronic | Kidney Transplantation | End-Stage Kidney DiseaseUnited States
-
Texas A&M UniversityWithdrawnChronic Kidney FailureUnited States
-
RenJi HospitalUnknownKidney Diseases,CysticChina
-
Centre Hospitalier le MansLe Mans UniversiteWithdrawnFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage3 | Chronic Kidney Failure | Chronic Kidney Disease, Stage 4 (Severe)
-
A.C. AbrahamsCompletedEnd Stage Renal Disease | Chronic Kidney Disease | End Stage Kidney Disease | Chronic Kidney FailureNetherlands
Clinical Trials on blood collection
-
University of South AlabamaRecruitingBurns | TraumaUnited States
-
University of FloridaEunice Kennedy Shriver National Institute of Child Health and Human Development...Active, not recruiting
-
University of OxfordMahidol Oxford Tropical Medicine Research UnitUnknown
-
Skane University HospitalLund University; Region SkaneActive, not recruitingSepsis | Critical Illness | Covid19 | Trauma | Influenza | Cardiac ArrestSweden
-
University of FloridaNational Institutes of Health (NIH); DiaCarta, Inc.Completed
-
Sir Run Run Shaw HospitalCompletedCatheter ComplicationsChina
-
Assistance Publique Hopitaux De MarseilleNot yet recruiting
-
Vanderbilt-Ingram Cancer CenterRecruitingClonal HematopoiesisUnited States
-
Erasmus Medical CenterRecruitingCirculating Tumor DNA (ctDNA) | Colorectal Cancer (Diagnosis) | Colorectal Liver Metastasis (CRLM)Netherlands
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)Active, not recruitingSeminoma | Germ Cell Tumor | Metachronous Malignant Neoplasm | Stage I Testicular Cancer AJCC v8 | Stage IA Testicular Cancer AJCC v8 | Stage IB Testicular Cancer AJCC v8 | Stage IS Testicular Cancer AJCC v8Canada, United States, Guam